Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives
Sphingosine-1-phosphate (S1P) and S1P receptors (S1PR) are bioactive lipid molecules that are ubiquitously expressed in the human body and play an important role in the immune system. S1P-S1PR signaling has been well characterized in immune trafficking and activation in both innate and adaptive immu...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/11/13/2058 |
| _version_ | 1797480556758302720 |
|---|---|
| author | Gary Álvarez Bravo René Robles Cedeño Marc Puig Casadevall Lluís Ramió-Torrentà |
| author_facet | Gary Álvarez Bravo René Robles Cedeño Marc Puig Casadevall Lluís Ramió-Torrentà |
| author_sort | Gary Álvarez Bravo |
| collection | DOAJ |
| description | Sphingosine-1-phosphate (S1P) and S1P receptors (S1PR) are bioactive lipid molecules that are ubiquitously expressed in the human body and play an important role in the immune system. S1P-S1PR signaling has been well characterized in immune trafficking and activation in both innate and adaptive immune systems. Despite this knowledge, the full scope in the pathogenesis of autoimmune disorders is not well characterized yet. From the discovery of fingolimod, the first S1P modulator, until siponimod, the new molecule recently approved for the treatment of secondary progressive multiple sclerosis (SPMS), there has been a great advance in understanding the S1P functions and their involvement in immune diseases, including multiple sclerosis (MS). Modulation on S1P is an interesting target for the treatment of various autoimmune disorders. Improved understanding of the mechanism of action of fingolimod has allowed the development of the more selective second-generation S1PR modulators. Subtype 1 of the S1PR (S1PR1) is expressed on the cell surface of lymphocytes, which are known to play a major role in MS pathogenesis. The understanding of S1PR1’s role facilitated the development of pharmacological strategies directed to this target, and theoretically reduced the safety concerns derived from the use of fingolimod. A great advance in the MS treatment was achieved in March 2019 when the Food and Drug Association (FDA) approved Siponimod, for both active secondary progressive MS and relapsing–remitting MS. Siponimod became the first oral disease modifying therapy (DMT) specifically approved for active forms of secondary progressive MS. Additionally, for the treatment of relapsing forms of MS, ozanimod was approved by FDA in March 2020. Currently, there are ongoing trials focused on other new-generation S1PR1 modulators. This review approaches the fundamental aspects of the sphingosine phosphate modulators and their main similarities and differences. |
| first_indexed | 2024-03-09T22:01:45Z |
| format | Article |
| id | doaj.art-99bb1badff1f4d5fab67e0fd0dd50ac5 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-09T22:01:45Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-99bb1badff1f4d5fab67e0fd0dd50ac52023-11-23T19:48:47ZengMDPI AGCells2073-44092022-06-011113205810.3390/cells11132058Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future PerspectivesGary Álvarez Bravo0René Robles Cedeño1Marc Puig Casadevall2Lluís Ramió-Torrentà3Girona Neuroimmunology and Multiple Sclerosis Unit, Department of Neurology, Dr. Josep Trueta University Hospital, Girona Biomedical Research Institute (IDIBGI), 17007 Girona, SpainGirona Neuroimmunology and Multiple Sclerosis Unit, Department of Neurology, Dr. Josep Trueta University Hospital, Girona Biomedical Research Institute (IDIBGI), 17007 Girona, SpainGirona Neuroimmunology and Multiple Sclerosis Unit, Department of Neurology, Dr. Josep Trueta University Hospital, Girona Biomedical Research Institute (IDIBGI), 17007 Girona, SpainGirona Neuroimmunology and Multiple Sclerosis Unit, Department of Neurology, Dr. Josep Trueta University Hospital, Girona Biomedical Research Institute (IDIBGI), 17007 Girona, SpainSphingosine-1-phosphate (S1P) and S1P receptors (S1PR) are bioactive lipid molecules that are ubiquitously expressed in the human body and play an important role in the immune system. S1P-S1PR signaling has been well characterized in immune trafficking and activation in both innate and adaptive immune systems. Despite this knowledge, the full scope in the pathogenesis of autoimmune disorders is not well characterized yet. From the discovery of fingolimod, the first S1P modulator, until siponimod, the new molecule recently approved for the treatment of secondary progressive multiple sclerosis (SPMS), there has been a great advance in understanding the S1P functions and their involvement in immune diseases, including multiple sclerosis (MS). Modulation on S1P is an interesting target for the treatment of various autoimmune disorders. Improved understanding of the mechanism of action of fingolimod has allowed the development of the more selective second-generation S1PR modulators. Subtype 1 of the S1PR (S1PR1) is expressed on the cell surface of lymphocytes, which are known to play a major role in MS pathogenesis. The understanding of S1PR1’s role facilitated the development of pharmacological strategies directed to this target, and theoretically reduced the safety concerns derived from the use of fingolimod. A great advance in the MS treatment was achieved in March 2019 when the Food and Drug Association (FDA) approved Siponimod, for both active secondary progressive MS and relapsing–remitting MS. Siponimod became the first oral disease modifying therapy (DMT) specifically approved for active forms of secondary progressive MS. Additionally, for the treatment of relapsing forms of MS, ozanimod was approved by FDA in March 2020. Currently, there are ongoing trials focused on other new-generation S1PR1 modulators. This review approaches the fundamental aspects of the sphingosine phosphate modulators and their main similarities and differences.https://www.mdpi.com/2073-4409/11/13/2058S1PS1PR1fingolimodozanimodsiponimodmultiple sclerosis |
| spellingShingle | Gary Álvarez Bravo René Robles Cedeño Marc Puig Casadevall Lluís Ramió-Torrentà Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives Cells S1P S1PR1 fingolimod ozanimod siponimod multiple sclerosis |
| title | Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives |
| title_full | Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives |
| title_fullStr | Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives |
| title_full_unstemmed | Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives |
| title_short | Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives |
| title_sort | sphingosine 1 phosphate s1p and s1p signaling pathway modulators from current insights to future perspectives |
| topic | S1P S1PR1 fingolimod ozanimod siponimod multiple sclerosis |
| url | https://www.mdpi.com/2073-4409/11/13/2058 |
| work_keys_str_mv | AT garyalvarezbravo sphingosine1phosphates1pands1psignalingpathwaymodulatorsfromcurrentinsightstofutureperspectives AT reneroblescedeno sphingosine1phosphates1pands1psignalingpathwaymodulatorsfromcurrentinsightstofutureperspectives AT marcpuigcasadevall sphingosine1phosphates1pands1psignalingpathwaymodulatorsfromcurrentinsightstofutureperspectives AT lluisramiotorrenta sphingosine1phosphates1pands1psignalingpathwaymodulatorsfromcurrentinsightstofutureperspectives |